Genetron Health to Participate in the 8th BioCentury-BayHelix China Healthcare Summit
November 15 2021 - 8:00AM
Genetron Holdings Limited (“Genetron Health” or the “Company”,
Nasdaq: GTH), a leading precision oncology platform company in
China that specializes in offering molecular profiling tests, early
cancer screening products and companion diagnostics development,
today announced its upcoming participation in the 8th
BioCentury-BayHelix China Healthcare Summit to be held November
16-19, 2021.
Genetron Health Chief Financial Officer, Evan
Xu, will be a panelist in the “Hands-On Bootcamp: Assessing the
Capital Markets Situation in China and the U.S.” discussion
available on-demand for conference participants. This workshop will
address key C-Suite questions and discuss strategies to reduce
regulatory risk while meeting investor expectations for global
competitiveness.
About Genetron Holdings
Limited
Genetron Holdings Limited (“Genetron Health” or
the “Company”) (Nasdaq:GTH) is a leading precision oncology
platform company in China that specializes in cancer molecular
profiling and harnesses advanced technologies in molecular biology
and data science to transform cancer treatment. The Company has
developed a comprehensive oncology portfolio that covers the entire
spectrum of cancer management, addressing needs and challenges from
early screening, diagnosis, and treatment recommendations, as well
as continuous disease monitoring and care. Genetron Health also
partners with global biopharmaceutical companies and offers
customized services and products. For more information, please
visit https://ir.genetronhealth.com/.
Safe Harbor Statement
This press release contains forward-looking
statements. These statements are made under the “safe harbor”
provisions of the U.S. Private Securities Litigation Reform Act of
1995. Statements that are not historical facts, including
statements about the Company’s beliefs and expectations, are
forward-looking statements. Forward-looking statements involve
inherent risks and uncertainties, and a number of factors could
cause actual results to differ materially from those contained in
any forward-looking statement. In some cases, forward-looking
statements can be identified by words or phrases such as “may”,
“will,” “expect,” “anticipate,” “target,” “aim,” “estimate,”
“intend,” “plan,” “believe,” “potential,” “continue,” “is/are
likely to” or other similar expressions. Further information
regarding these and other risks, uncertainties or factors is
included in the Company’s filings with the SEC. All information
provided in this press release is as of the date of this press
release, and the Company does not undertake any duty to update such
information, except as required under applicable law.
Investor Relations ContactUS:Hoki LukHead of
Investor RelationsEmail: hluk@genetronhealth.us Phone: +1
(408) 891-9255
Philip Trip TaylorVice President | Gilmartin GroupEmail:
ir@genetronhealth.com
Genetron (NASDAQ:GTH)
Historical Stock Chart
From May 2024 to Jun 2024
Genetron (NASDAQ:GTH)
Historical Stock Chart
From Jun 2023 to Jun 2024